415 related articles for article (PubMed ID: 33414905)
1. New psychoactive substances: a review and updates.
Shafi A; Berry AJ; Sumnall H; Wood DM; Tracy DK
Ther Adv Psychopharmacol; 2020; 10():2045125320967197. PubMed ID: 33414905
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Chung EY; Cha HJ; Min HK; Yun J
Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
[TBL] [Abstract][Full Text] [Related]
3. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
[No Abstract] [Full Text] [Related]
4. [New psychoactive substances in emergency medicine].
Marinowitz R; Strube J; Schaper A
Nervenarzt; 2024 Jan; 95(1):28-34. PubMed ID: 38189941
[TBL] [Abstract][Full Text] [Related]
5. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.
Logan BK; Mohr ALA; Friscia M; Krotulski AJ; Papsun DM; Kacinko SL; Ropero-Miller JD; Huestis MA
J Anal Toxicol; 2017 Sep; 41(7):573-610. PubMed ID: 28459969
[TBL] [Abstract][Full Text] [Related]
6. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
Zawilska JB; Andrzejczak D
Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
[TBL] [Abstract][Full Text] [Related]
7. Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.
Miliano C; Serpelloni G; Rimondo C; Mereu M; Marti M; De Luca MA
Front Neurosci; 2016; 10():153. PubMed ID: 27147945
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of NPS Based Confirmed Overdose Cases: The STRIDA Project.
Helander A; Bäckberg M
Handb Exp Pharmacol; 2018; 252():461-473. PubMed ID: 30135990
[TBL] [Abstract][Full Text] [Related]
9. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
10. The impact of the 2016 Psychoactive Substances Act on synthetic cannabinoid use within the homeless population: Markets, content and user harms.
Ralphs R; Gray P; Sutcliffe OB
Int J Drug Policy; 2021 Nov; 97():103305. PubMed ID: 34146792
[TBL] [Abstract][Full Text] [Related]
11. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
12. The Psychoactive Surveillance Consortium and Analysis Network (PSCAN): the first year.
Monte AA; Hopkinson A; Saben J; Shelton SK; Thornton S; Schneir A; Pomerleau A; Hendrickson RG; Arens AM; Cole JB; Chenoweth J; Martin S; Adams A; Banister SD; Gerona RR
Addiction; 2020 Feb; 115(2):270-278. PubMed ID: 31769125
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.
Giorgetti A; Pascali JP; Fais P; Pelletti G; Gabbin A; Franchetti G; Cecchetto G; Viel G
Life (Basel); 2021 May; 11(5):. PubMed ID: 34068903
[TBL] [Abstract][Full Text] [Related]
15. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
Schifano F; Papanti GD; Orsolini L; Corkery JM
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
[TBL] [Abstract][Full Text] [Related]
16. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.
Mohr ALA; Logan BK; Fogarty MF; Krotulski AJ; Papsun DM; Kacinko SL; Huestis MA; Ropero-Miller JD
J Anal Toxicol; 2022 Jul; 46(6):e116-e185. PubMed ID: 35445267
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs of New Psychoactive Substances (NPS): A New Challenge.
Elliott SP; Holdbrook T; Brandt SD
J Forensic Sci; 2020 May; 65(3):913-920. PubMed ID: 31943218
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.
Bonaccorso S; Metastasio A; Ricciardi A; Stewart N; Jamal L; Rujully NU; Theleritis C; Ferracuti S; Ducci G; Schifano F
Brain Sci; 2018 Jul; 8(7):. PubMed ID: 30011896
[TBL] [Abstract][Full Text] [Related]
19. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
Zawilska JB
Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Acute Toxicity Associated with New Psychoactive Substances.
Hill SL; Dargan PI
Handb Exp Pharmacol; 2018; 252():475-494. PubMed ID: 29896654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
